Acceleron Pharma Initiates Phase 2 Study of ACE-536 to Treat Anemia in Patients With Myelodysplastic Syndromes
Published: Jan 29, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS). MDS are a group of hematologic malignancies of the bone marrow that result in low levels of one or more types of blood cells resulting most commonly in severe and chronic anemia (low levels of red blood cells). Acceleron is developing ACE-536 in a global collaboration with Celgene Corporation (NASDAQ: CELG). Acceleron earned a $10 million milestone for initiating this phase 2 study and is still eligible to receive development, regulatory and commercial milestones of up to $200 million for the ACE-536 program.